SlideShare uma empresa Scribd logo
1 de 12
Baixar para ler offline
Presentation by
Darren Cunningham
CEO
dcunningham@inflectionbio.com
2
Overview
1 in 3 will get cancer – many will not survive
***
Our mission
develop groundbreaking new treatments for those
suffering with cancer
3
Business Model
DISC TARGET HITS LEAD
PRE-
CLIN
IND PHASE 1 PHASE 2 PHASE 3 APP LAUNCH
LEAD
IND
PACKAGE
EARLY
CLINICAL
PRE-
CLINICAL
10-15 YEAR DEVELOPMENT
Value Inflection:
LICENSE IN PARTNER/
EXIT/IPO
4 – 5 YEAR DEVELOPMENT
4
Phase I Value Creation Potential
Phase I
Oncology
Exits
$100m -
>$300m
5 Spanish National Cancer Research Centre
Collaboration with CNIO - June 2013
 Comprising first-in-class agents protected by composition
of matter patents
6
Pipeline – Targeted Therapeutics
RESEARCH PRE-CLIN IND PHASE ITARGET
MULTIPLE MYELOMA
NSCLC
IBL-202 (PIM/PI3K)
IBL-300s (PIM/PI3K/mTOR)
HAEM MALIGNANCIESIBL-100s (Pan-PIM)
OTHER K-RAS TUMOURS
B-CELL LYMPHOMAS
B-CELL LYMPHOMAS
Secure Partner after
Phase I
Secure Partner at IND
7
PIM Kinase a driver of resistance in AKT/PI3K
1. PIM expression dramatically
elevated by PI3K/AKT pathway
inhibition
2. PIM mediates feedback loop
driving acquired resistance to a
number of treatment modalities.
Underpins rationale for co-
targeting PI3K and PIM;
huge clinical opportunity
8
IBL-300s – Targeting Molecular Subsets in NSCLC(Stage IV)
EGFR TKI ResistantMutant K-RasDe novo PI3k activation
Lung cancer leading cause of cancer death (1.6m ww)
- NSCLC ~80% = $10bn market by 2020
Role for PI3K and PIM co-targeting in NSCLC Rationale for IBL-300s
 NSCLC - K-Ras mutated
in 15-30%
 Downstream activation
include
PI3K/AKT/mTOR
 PIM inhibition shuts
down growth in mutant
K-Ras NSCLC cell lines
 NSCLC - EGFR
mutations in ~10% de
novo
 Cancer recurs (~12mo)
with ~10% due to PI3K
activation
 PIM elevated in EGFR
TKI resistant lines
 Squamous cc – PIK3CA/
PTEN mutations ~30%
 PIM and PI3K inhibitors
act synergistically in vitro
and in vivo
 PIM mediates PI3K/AKT
resistance
9
Research Collaboration Network
 Network spanning US, EU, Australia
 NSCLC, pancreatic, ovarian, multiple myeloma, DLBCL,
MCL, CLL, neuroblastoma, breast cancer, mechanistic
Leadership
Darren
Cunningham
CEO
15 year record
in licensing,
M&A, IP,
fundraising, IR
Amarin, Elan,
PWC
B. Comm, M.
Acc, FCA
Dr. Michael
O’Neill
Director R&D
22 year drug
discovery and
development
 Eli Lilly,
Almirall, Merck
 BA
Psychology,
PhD
MANAGEMENT ONCOLOGY ADVISORY PANEL
Prof. Josep
Tabernero
 Director, Vall
d’Hebron Institute of
Oncology
 Led clinical
development of
PI3K pathway
inhibitors
 ESMO Executive
Board
Prof. Funda
Meric-Bernstam
 Professor of
Surgical Oncology;
and
 Chair Department
of Investigational
Cancer
Therapeutics, M.
D. Anderson
Cancer Center
Dr. Martin Page
 30+ years
experience in
oncology R&D
 Previous VP, Global
Head of Oncology
Res. J&J
 Roles with OSI
Pharma, Oxford
Glycosciences, and
Glaxo-Wellcome
 Incorporated 2012
 Headquartered in Dublin, with base in London
 2 full time employees
– Internship program, 3 in 2015
– PhD in TCD via Innovation Partnership
 6 board members; panel of international scientific
advisors
 6 CROs (UK, France, China, India)
 >10 research collaborations (US, Ireland, UK,
Germany, Sweden, Australia)
 ~€2.2m raised to date (EI, VC and privates)
11
Corporate profile
Thank you
Darren Cunningham
dcunningham@inflectionbio.com

Mais conteúdo relacionado

Mais procurados

CAR T-cell Therapy_A New Era in Cancer Immunotherapy
CAR T-cell Therapy_A New Era in Cancer ImmunotherapyCAR T-cell Therapy_A New Era in Cancer Immunotherapy
CAR T-cell Therapy_A New Era in Cancer ImmunotherapyTuhin Samanta
 
Scientific program for Cancer Research 2018
Scientific program for Cancer Research 2018Scientific program for Cancer Research 2018
Scientific program for Cancer Research 2018Vijayanand Jedar
 
Chimeric Antigen Receptor (car) Technique-Creative Biolabs
Chimeric Antigen Receptor (car) Technique-Creative BiolabsChimeric Antigen Receptor (car) Technique-Creative Biolabs
Chimeric Antigen Receptor (car) Technique-Creative BiolabsCreative-Biolabs
 
Tcr Technology - Creative Biolabs
Tcr Technology - Creative BiolabsTcr Technology - Creative Biolabs
Tcr Technology - Creative BiolabsCreative-Biolabs
 
Use of signaling targets in cancer therapy
Use of signaling targets in cancer therapyUse of signaling targets in cancer therapy
Use of signaling targets in cancer therapySree Parvathy
 
Immunohistochemistry of Thyroid Gland tumor
Immunohistochemistry of Thyroid Gland tumorImmunohistochemistry of Thyroid Gland tumor
Immunohistochemistry of Thyroid Gland tumorhome education
 
Proteins: structure and functions
Proteins: structure and functions Proteins: structure and functions
Proteins: structure and functions Claudia Hndz
 
Estimating Mutation Load from Tumor Research Samples using a Targeted Next-Ge...
Estimating Mutation Load from Tumor Research Samples using a Targeted Next-Ge...Estimating Mutation Load from Tumor Research Samples using a Targeted Next-Ge...
Estimating Mutation Load from Tumor Research Samples using a Targeted Next-Ge...Thermo Fisher Scientific
 
Immunotherapy: Focus on CAR-T cells
Immunotherapy: Focus on CAR-T cellsImmunotherapy: Focus on CAR-T cells
Immunotherapy: Focus on CAR-T cellsZeena Nackerdien
 
Molecular advancement in meningioma
Molecular advancement in meningiomaMolecular advancement in meningioma
Molecular advancement in meningiomavikas dwivedi
 
Translational science in neuroendocrne tumors: opportunities and pitfalls - B...
Translational science in neuroendocrne tumors: opportunities and pitfalls - B...Translational science in neuroendocrne tumors: opportunities and pitfalls - B...
Translational science in neuroendocrne tumors: opportunities and pitfalls - B...Prof. Eric Raymond Oncologie Medicale
 
Potential cancer cells and therapy to treat melanoma
Potential cancer cells and therapy to treat melanomaPotential cancer cells and therapy to treat melanoma
Potential cancer cells and therapy to treat melanomaluisa2195
 

Mais procurados (20)

CAR T-cell Therapy_A New Era in Cancer Immunotherapy
CAR T-cell Therapy_A New Era in Cancer ImmunotherapyCAR T-cell Therapy_A New Era in Cancer Immunotherapy
CAR T-cell Therapy_A New Era in Cancer Immunotherapy
 
Scientific program for Cancer Research 2018
Scientific program for Cancer Research 2018Scientific program for Cancer Research 2018
Scientific program for Cancer Research 2018
 
Chimeric Antigen Receptor (car) Technique-Creative Biolabs
Chimeric Antigen Receptor (car) Technique-Creative BiolabsChimeric Antigen Receptor (car) Technique-Creative Biolabs
Chimeric Antigen Receptor (car) Technique-Creative Biolabs
 
Tcr Technology - Creative Biolabs
Tcr Technology - Creative BiolabsTcr Technology - Creative Biolabs
Tcr Technology - Creative Biolabs
 
Car T-cell therapy
Car T-cell therapyCar T-cell therapy
Car T-cell therapy
 
Cancer
CancerCancer
Cancer
 
Use of signaling targets in cancer therapy
Use of signaling targets in cancer therapyUse of signaling targets in cancer therapy
Use of signaling targets in cancer therapy
 
Immunohistochemistry of Thyroid Gland tumor
Immunohistochemistry of Thyroid Gland tumorImmunohistochemistry of Thyroid Gland tumor
Immunohistochemistry of Thyroid Gland tumor
 
Proteins: structure and functions
Proteins: structure and functions Proteins: structure and functions
Proteins: structure and functions
 
Car T cell
Car T cellCar T cell
Car T cell
 
Estimating Mutation Load from Tumor Research Samples using a Targeted Next-Ge...
Estimating Mutation Load from Tumor Research Samples using a Targeted Next-Ge...Estimating Mutation Load from Tumor Research Samples using a Targeted Next-Ge...
Estimating Mutation Load from Tumor Research Samples using a Targeted Next-Ge...
 
CAR- T Cell
CAR- T CellCAR- T Cell
CAR- T Cell
 
Car t cell tumor board
Car  t cell tumor boardCar  t cell tumor board
Car t cell tumor board
 
Retroviral transfection
Retroviral transfectionRetroviral transfection
Retroviral transfection
 
Car T cell
Car T cellCar T cell
Car T cell
 
Immunotherapy: Focus on CAR-T cells
Immunotherapy: Focus on CAR-T cellsImmunotherapy: Focus on CAR-T cells
Immunotherapy: Focus on CAR-T cells
 
Molecular advancement in meningioma
Molecular advancement in meningiomaMolecular advancement in meningioma
Molecular advancement in meningioma
 
Translational science in neuroendocrne tumors: opportunities and pitfalls - B...
Translational science in neuroendocrne tumors: opportunities and pitfalls - B...Translational science in neuroendocrne tumors: opportunities and pitfalls - B...
Translational science in neuroendocrne tumors: opportunities and pitfalls - B...
 
Potential cancer cells and therapy to treat melanoma
Potential cancer cells and therapy to treat melanomaPotential cancer cells and therapy to treat melanoma
Potential cancer cells and therapy to treat melanoma
 
Hallmarks of cancer
Hallmarks of cancerHallmarks of cancer
Hallmarks of cancer
 

Semelhante a Darren Cunningham, Inflection Bio Sciences

PharmaMar-corporate-presentation
PharmaMar-corporate-presentationPharmaMar-corporate-presentation
PharmaMar-corporate-presentationVincenzo Esposito
 
Vital Signs Edition #3
Vital Signs   Edition #3Vital Signs   Edition #3
Vital Signs Edition #3ScottJordan
 
Microbiome Diagnostics Platform for Microbiome Health and Colon Cancer Preven...
Microbiome Diagnostics Platform for Microbiome Health and Colon Cancer Preven...Microbiome Diagnostics Platform for Microbiome Health and Colon Cancer Preven...
Microbiome Diagnostics Platform for Microbiome Health and Colon Cancer Preven...Laura Berry
 
CCO immune checkpoint_inhibitors_in_cancer_care
CCO immune checkpoint_inhibitors_in_cancer_careCCO immune checkpoint_inhibitors_in_cancer_care
CCO immune checkpoint_inhibitors_in_cancer_careAdonis Guancia
 
Hitting the Bullseye: Are Cell Penetrating Peptides (CPP) the Future of Targe...
Hitting the Bullseye: Are Cell Penetrating Peptides (CPP) the Future of Targe...Hitting the Bullseye: Are Cell Penetrating Peptides (CPP) the Future of Targe...
Hitting the Bullseye: Are Cell Penetrating Peptides (CPP) the Future of Targe...CrimsonpublishersCancer
 
Inovio Pharmaceuticals - October 2015
Inovio Pharmaceuticals - October 2015Inovio Pharmaceuticals - October 2015
Inovio Pharmaceuticals - October 2015Company Spotlight
 
Inovio Pharmaceuticals, Inc. - Revolutionizing the Fight Against Cancers and ...
Inovio Pharmaceuticals, Inc. - Revolutionizing the Fight Against Cancers and ...Inovio Pharmaceuticals, Inc. - Revolutionizing the Fight Against Cancers and ...
Inovio Pharmaceuticals, Inc. - Revolutionizing the Fight Against Cancers and ...Company Spotlight
 
Msd msi high solid tumors
Msd msi high solid tumorsMsd msi high solid tumors
Msd msi high solid tumorsMohamed Abdulla
 
iOncologi_Pitch Deck_2024 slide show for hostinger
iOncologi_Pitch Deck_2024 slide show for hostingeriOncologi_Pitch Deck_2024 slide show for hostinger
iOncologi_Pitch Deck_2024 slide show for hostingerssuser9354ce
 
Alexandre_Arcaro_Intl_Innovation_142_Research_Media_HR
Alexandre_Arcaro_Intl_Innovation_142_Research_Media_HRAlexandre_Arcaro_Intl_Innovation_142_Research_Media_HR
Alexandre_Arcaro_Intl_Innovation_142_Research_Media_HRAlexandre Arcaro
 
180528 red eye_podium
180528 red eye_podium180528 red eye_podium
180528 red eye_podiumtargovax2017
 
Global lung cancer vaccine market & pipeline insight 2015
Global lung cancer vaccine market & pipeline insight 2015Global lung cancer vaccine market & pipeline insight 2015
Global lung cancer vaccine market & pipeline insight 2015KuicK Research
 
1805 bio equity_podium v3
1805 bio equity_podium v31805 bio equity_podium v3
1805 bio equity_podium v3targovax2017
 
2022-ESMO-Summit-Africa-Target-Therapy-Colorectal-Cancer-FL.pdf
2022-ESMO-Summit-Africa-Target-Therapy-Colorectal-Cancer-FL.pdf2022-ESMO-Summit-Africa-Target-Therapy-Colorectal-Cancer-FL.pdf
2022-ESMO-Summit-Africa-Target-Therapy-Colorectal-Cancer-FL.pdfdrblouse
 
Inovio Pharmaceuticals - Revolutionizing Vaccines
Inovio Pharmaceuticals - Revolutionizing VaccinesInovio Pharmaceuticals - Revolutionizing Vaccines
Inovio Pharmaceuticals - Revolutionizing VaccinesCompany Spotlight
 

Semelhante a Darren Cunningham, Inflection Bio Sciences (20)

PharmaMar-corporate-presentation
PharmaMar-corporate-presentationPharmaMar-corporate-presentation
PharmaMar-corporate-presentation
 
CEL-SCI Corporation.pdf
CEL-SCI Corporation.pdfCEL-SCI Corporation.pdf
CEL-SCI Corporation.pdf
 
Vital Signs Edition #3
Vital Signs   Edition #3Vital Signs   Edition #3
Vital Signs Edition #3
 
Microbiome Diagnostics Platform for Microbiome Health and Colon Cancer Preven...
Microbiome Diagnostics Platform for Microbiome Health and Colon Cancer Preven...Microbiome Diagnostics Platform for Microbiome Health and Colon Cancer Preven...
Microbiome Diagnostics Platform for Microbiome Health and Colon Cancer Preven...
 
CCO immune checkpoint_inhibitors_in_cancer_care
CCO immune checkpoint_inhibitors_in_cancer_careCCO immune checkpoint_inhibitors_in_cancer_care
CCO immune checkpoint_inhibitors_in_cancer_care
 
Elemental Breath
Elemental BreathElemental Breath
Elemental Breath
 
Bilal CAPR-14-0231.full
Bilal CAPR-14-0231.fullBilal CAPR-14-0231.full
Bilal CAPR-14-0231.full
 
Hitting the Bullseye: Are Cell Penetrating Peptides (CPP) the Future of Targe...
Hitting the Bullseye: Are Cell Penetrating Peptides (CPP) the Future of Targe...Hitting the Bullseye: Are Cell Penetrating Peptides (CPP) the Future of Targe...
Hitting the Bullseye: Are Cell Penetrating Peptides (CPP) the Future of Targe...
 
Inovio Pharmaceuticals - October 2015
Inovio Pharmaceuticals - October 2015Inovio Pharmaceuticals - October 2015
Inovio Pharmaceuticals - October 2015
 
Inovio Pharmaceuticals, Inc. - Revolutionizing the Fight Against Cancers and ...
Inovio Pharmaceuticals, Inc. - Revolutionizing the Fight Against Cancers and ...Inovio Pharmaceuticals, Inc. - Revolutionizing the Fight Against Cancers and ...
Inovio Pharmaceuticals, Inc. - Revolutionizing the Fight Against Cancers and ...
 
Msd msi high solid tumors
Msd msi high solid tumorsMsd msi high solid tumors
Msd msi high solid tumors
 
Swaan
SwaanSwaan
Swaan
 
Corporate Presentation
Corporate Presentation Corporate Presentation
Corporate Presentation
 
iOncologi_Pitch Deck_2024 slide show for hostinger
iOncologi_Pitch Deck_2024 slide show for hostingeriOncologi_Pitch Deck_2024 slide show for hostinger
iOncologi_Pitch Deck_2024 slide show for hostinger
 
Alexandre_Arcaro_Intl_Innovation_142_Research_Media_HR
Alexandre_Arcaro_Intl_Innovation_142_Research_Media_HRAlexandre_Arcaro_Intl_Innovation_142_Research_Media_HR
Alexandre_Arcaro_Intl_Innovation_142_Research_Media_HR
 
180528 red eye_podium
180528 red eye_podium180528 red eye_podium
180528 red eye_podium
 
Global lung cancer vaccine market & pipeline insight 2015
Global lung cancer vaccine market & pipeline insight 2015Global lung cancer vaccine market & pipeline insight 2015
Global lung cancer vaccine market & pipeline insight 2015
 
1805 bio equity_podium v3
1805 bio equity_podium v31805 bio equity_podium v3
1805 bio equity_podium v3
 
2022-ESMO-Summit-Africa-Target-Therapy-Colorectal-Cancer-FL.pdf
2022-ESMO-Summit-Africa-Target-Therapy-Colorectal-Cancer-FL.pdf2022-ESMO-Summit-Africa-Target-Therapy-Colorectal-Cancer-FL.pdf
2022-ESMO-Summit-Africa-Target-Therapy-Colorectal-Cancer-FL.pdf
 
Inovio Pharmaceuticals - Revolutionizing Vaccines
Inovio Pharmaceuticals - Revolutionizing VaccinesInovio Pharmaceuticals - Revolutionizing Vaccines
Inovio Pharmaceuticals - Revolutionizing Vaccines
 

Mais de Investnet

Grainne Flynn , Blood Sugar Trampoline:Patient Speaker
Grainne Flynn , Blood Sugar Trampoline:Patient SpeakerGrainne Flynn , Blood Sugar Trampoline:Patient Speaker
Grainne Flynn , Blood Sugar Trampoline:Patient SpeakerInvestnet
 
Dr Neil Black , Consultant Physician
Dr Neil Black , Consultant PhysicianDr Neil Black , Consultant Physician
Dr Neil Black , Consultant PhysicianInvestnet
 
Gerald Tomkin , Director of the Diabetes Institute Beacon Hospital
Gerald Tomkin , Director of the Diabetes Institute Beacon HospitalGerald Tomkin , Director of the Diabetes Institute Beacon Hospital
Gerald Tomkin , Director of the Diabetes Institute Beacon HospitalInvestnet
 
Dr. Ronan Canavan , Clinical lead of the National Clinical Programme for Diab...
Dr. Ronan Canavan , Clinical lead of the National Clinical Programme for Diab...Dr. Ronan Canavan , Clinical lead of the National Clinical Programme for Diab...
Dr. Ronan Canavan , Clinical lead of the National Clinical Programme for Diab...Investnet
 
Healthbridge
HealthbridgeHealthbridge
HealthbridgeInvestnet
 
Think Biosolution
Think BiosolutionThink Biosolution
Think BiosolutionInvestnet
 
Malcolm R. Kell, Breast Cancer Survivor
Malcolm R. Kell, Breast Cancer SurvivorMalcolm R. Kell, Breast Cancer Survivor
Malcolm R. Kell, Breast Cancer SurvivorInvestnet
 
Control Drink
Control DrinkControl Drink
Control DrinkInvestnet
 
Robert Kelly, Videodoc
Robert Kelly, VideodocRobert Kelly, Videodoc
Robert Kelly, VideodocInvestnet
 
Cathal Brennan , Medical Device Assessor- Human Products Authorisation and Re...
Cathal Brennan , Medical Device Assessor- Human Products Authorisation and Re...Cathal Brennan , Medical Device Assessor- Human Products Authorisation and Re...
Cathal Brennan , Medical Device Assessor- Human Products Authorisation and Re...Investnet
 
Anastasia Dedyukhina , Consciously Digital
Anastasia Dedyukhina , Consciously DigitalAnastasia Dedyukhina , Consciously Digital
Anastasia Dedyukhina , Consciously DigitalInvestnet
 
Sasha Oliver, Avloni
Sasha Oliver, AvloniSasha Oliver, Avloni
Sasha Oliver, AvloniInvestnet
 
Jemma Gatliff, Keregen
Jemma Gatliff, KeregenJemma Gatliff, Keregen
Jemma Gatliff, KeregenInvestnet
 
Phision Theraputics
Phision TheraputicsPhision Theraputics
Phision TheraputicsInvestnet
 
Niamh Malone , Brainey App
Niamh Malone , Brainey App Niamh Malone , Brainey App
Niamh Malone , Brainey App Investnet
 
Toby Basey-Fisher , CEO, Co Founder, Eva Diagnostics
Toby Basey-Fisher , CEO, Co Founder, Eva DiagnosticsToby Basey-Fisher , CEO, Co Founder, Eva Diagnostics
Toby Basey-Fisher , CEO, Co Founder, Eva DiagnosticsInvestnet
 
Ena Prosser, Fountain Healthcare Partners
Ena Prosser, Fountain Healthcare PartnersEna Prosser, Fountain Healthcare Partners
Ena Prosser, Fountain Healthcare PartnersInvestnet
 
Cathal Friel, Raglan Capital
Cathal Friel, Raglan CapitalCathal Friel, Raglan Capital
Cathal Friel, Raglan CapitalInvestnet
 
Kieran O’Connell , DIT Hothouse
Kieran O’Connell , DIT HothouseKieran O’Connell , DIT Hothouse
Kieran O’Connell , DIT HothouseInvestnet
 
Dr. Lawrence Ampofo , Semantica Research
Dr. Lawrence Ampofo , Semantica ResearchDr. Lawrence Ampofo , Semantica Research
Dr. Lawrence Ampofo , Semantica ResearchInvestnet
 

Mais de Investnet (20)

Grainne Flynn , Blood Sugar Trampoline:Patient Speaker
Grainne Flynn , Blood Sugar Trampoline:Patient SpeakerGrainne Flynn , Blood Sugar Trampoline:Patient Speaker
Grainne Flynn , Blood Sugar Trampoline:Patient Speaker
 
Dr Neil Black , Consultant Physician
Dr Neil Black , Consultant PhysicianDr Neil Black , Consultant Physician
Dr Neil Black , Consultant Physician
 
Gerald Tomkin , Director of the Diabetes Institute Beacon Hospital
Gerald Tomkin , Director of the Diabetes Institute Beacon HospitalGerald Tomkin , Director of the Diabetes Institute Beacon Hospital
Gerald Tomkin , Director of the Diabetes Institute Beacon Hospital
 
Dr. Ronan Canavan , Clinical lead of the National Clinical Programme for Diab...
Dr. Ronan Canavan , Clinical lead of the National Clinical Programme for Diab...Dr. Ronan Canavan , Clinical lead of the National Clinical Programme for Diab...
Dr. Ronan Canavan , Clinical lead of the National Clinical Programme for Diab...
 
Healthbridge
HealthbridgeHealthbridge
Healthbridge
 
Think Biosolution
Think BiosolutionThink Biosolution
Think Biosolution
 
Malcolm R. Kell, Breast Cancer Survivor
Malcolm R. Kell, Breast Cancer SurvivorMalcolm R. Kell, Breast Cancer Survivor
Malcolm R. Kell, Breast Cancer Survivor
 
Control Drink
Control DrinkControl Drink
Control Drink
 
Robert Kelly, Videodoc
Robert Kelly, VideodocRobert Kelly, Videodoc
Robert Kelly, Videodoc
 
Cathal Brennan , Medical Device Assessor- Human Products Authorisation and Re...
Cathal Brennan , Medical Device Assessor- Human Products Authorisation and Re...Cathal Brennan , Medical Device Assessor- Human Products Authorisation and Re...
Cathal Brennan , Medical Device Assessor- Human Products Authorisation and Re...
 
Anastasia Dedyukhina , Consciously Digital
Anastasia Dedyukhina , Consciously DigitalAnastasia Dedyukhina , Consciously Digital
Anastasia Dedyukhina , Consciously Digital
 
Sasha Oliver, Avloni
Sasha Oliver, AvloniSasha Oliver, Avloni
Sasha Oliver, Avloni
 
Jemma Gatliff, Keregen
Jemma Gatliff, KeregenJemma Gatliff, Keregen
Jemma Gatliff, Keregen
 
Phision Theraputics
Phision TheraputicsPhision Theraputics
Phision Theraputics
 
Niamh Malone , Brainey App
Niamh Malone , Brainey App Niamh Malone , Brainey App
Niamh Malone , Brainey App
 
Toby Basey-Fisher , CEO, Co Founder, Eva Diagnostics
Toby Basey-Fisher , CEO, Co Founder, Eva DiagnosticsToby Basey-Fisher , CEO, Co Founder, Eva Diagnostics
Toby Basey-Fisher , CEO, Co Founder, Eva Diagnostics
 
Ena Prosser, Fountain Healthcare Partners
Ena Prosser, Fountain Healthcare PartnersEna Prosser, Fountain Healthcare Partners
Ena Prosser, Fountain Healthcare Partners
 
Cathal Friel, Raglan Capital
Cathal Friel, Raglan CapitalCathal Friel, Raglan Capital
Cathal Friel, Raglan Capital
 
Kieran O’Connell , DIT Hothouse
Kieran O’Connell , DIT HothouseKieran O’Connell , DIT Hothouse
Kieran O’Connell , DIT Hothouse
 
Dr. Lawrence Ampofo , Semantica Research
Dr. Lawrence Ampofo , Semantica ResearchDr. Lawrence Ampofo , Semantica Research
Dr. Lawrence Ampofo , Semantica Research
 

Último

Anatomy Shelf Notevbhhhhhhhhhhhhhhhs.pdf
Anatomy Shelf Notevbhhhhhhhhhhhhhhhs.pdfAnatomy Shelf Notevbhhhhhhhhhhhhhhhs.pdf
Anatomy Shelf Notevbhhhhhhhhhhhhhhhs.pdfhezamzaki1
 
Three Keys to a Successful Margin: Charges, Costs, and Labor
Three Keys to a Successful Margin: Charges, Costs, and LaborThree Keys to a Successful Margin: Charges, Costs, and Labor
Three Keys to a Successful Margin: Charges, Costs, and LaborHealth Catalyst
 
Hematinics and Erythropoietin- Pharmacology of Hematinics
Hematinics and Erythropoietin- Pharmacology of HematinicsHematinics and Erythropoietin- Pharmacology of Hematinics
Hematinics and Erythropoietin- Pharmacology of Hematinicsnetraangadi2
 
Understanding Warts and Moles: Differences, Types, and Common Locations
Understanding Warts and Moles: Differences, Types, and Common LocationsUnderstanding Warts and Moles: Differences, Types, and Common Locations
Understanding Warts and Moles: Differences, Types, and Common LocationsNeha Sharma
 
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdfDolisha Warbi
 
Basics of Giant Cell Tumor of bone (GCTB)
Basics of Giant Cell Tumor of bone (GCTB)Basics of Giant Cell Tumor of bone (GCTB)
Basics of Giant Cell Tumor of bone (GCTB)bishwabandhuniraula
 
Empathy Is a Stress Response - Choose Compassion instead
Empathy Is a Stress Response - Choose Compassion insteadEmpathy Is a Stress Response - Choose Compassion instead
Empathy Is a Stress Response - Choose Compassion insteadAlex Clapson
 
ARTHRITIS.pptx Prepared by monika gopal Tutor
ARTHRITIS.pptx Prepared  by monika gopal TutorARTHRITIS.pptx Prepared  by monika gopal Tutor
ARTHRITIS.pptx Prepared by monika gopal TutorNehaKewat
 
Pharmacovigilance audits inspections.pptx
Pharmacovigilance audits inspections.pptxPharmacovigilance audits inspections.pptx
Pharmacovigilance audits inspections.pptxCliniminds India
 
Toothpaste for bleeding gums and sensitive teeth. Teeth whitening, Mouthwash....
Toothpaste for bleeding gums and sensitive teeth. Teeth whitening, Mouthwash....Toothpaste for bleeding gums and sensitive teeth. Teeth whitening, Mouthwash....
Toothpaste for bleeding gums and sensitive teeth. Teeth whitening, Mouthwash....sharyurangari111
 
ACCA Version of AI & Healthcare: An Overview for the Curious
ACCA Version of AI & Healthcare: An Overview for the CuriousACCA Version of AI & Healthcare: An Overview for the Curious
ACCA Version of AI & Healthcare: An Overview for the CuriousKR_Barker
 
LARYNGEAL CANCER.pptx Prepared by Neha Kewat
LARYNGEAL CANCER.pptx  Prepared by Neha KewatLARYNGEAL CANCER.pptx  Prepared by Neha Kewat
LARYNGEAL CANCER.pptx Prepared by Neha KewatNehaKewat
 
Artificial Intelligence in Healthcare: Challenges, Risks, Benefits
Artificial Intelligence in Healthcare: Challenges, Risks, BenefitsArtificial Intelligence in Healthcare: Challenges, Risks, Benefits
Artificial Intelligence in Healthcare: Challenges, Risks, BenefitsIris Thiele Isip-Tan
 
Diseases of the Respiratory System (J00-J99),.pptx
Diseases of the Respiratory System (J00-J99),.pptxDiseases of the Respiratory System (J00-J99),.pptx
Diseases of the Respiratory System (J00-J99),.pptxEMADABATHINI PRABHU TEJA
 
Eating Disorders in Athletes I Sports Psychology
Eating Disorders in Athletes I Sports PsychologyEating Disorders in Athletes I Sports Psychology
Eating Disorders in Athletes I Sports Psychologyshantisphysio
 
CECT NECK NECK ANGIOGRAPHY CAROTID ANGIOGRAPHY
CECT NECK NECK ANGIOGRAPHY CAROTID ANGIOGRAPHYCECT NECK NECK ANGIOGRAPHY CAROTID ANGIOGRAPHY
CECT NECK NECK ANGIOGRAPHY CAROTID ANGIOGRAPHYRMC
 
Living Well Every Day: Lyons Wellness Practice | Nurtures Your Complete Health
Living Well Every Day: Lyons Wellness Practice | Nurtures Your Complete HealthLiving Well Every Day: Lyons Wellness Practice | Nurtures Your Complete Health
Living Well Every Day: Lyons Wellness Practice | Nurtures Your Complete HealthLyons Health
 

Último (20)

Anatomy Shelf Notevbhhhhhhhhhhhhhhhs.pdf
Anatomy Shelf Notevbhhhhhhhhhhhhhhhs.pdfAnatomy Shelf Notevbhhhhhhhhhhhhhhhs.pdf
Anatomy Shelf Notevbhhhhhhhhhhhhhhhs.pdf
 
Three Keys to a Successful Margin: Charges, Costs, and Labor
Three Keys to a Successful Margin: Charges, Costs, and LaborThree Keys to a Successful Margin: Charges, Costs, and Labor
Three Keys to a Successful Margin: Charges, Costs, and Labor
 
Hematinics and Erythropoietin- Pharmacology of Hematinics
Hematinics and Erythropoietin- Pharmacology of HematinicsHematinics and Erythropoietin- Pharmacology of Hematinics
Hematinics and Erythropoietin- Pharmacology of Hematinics
 
Understanding Warts and Moles: Differences, Types, and Common Locations
Understanding Warts and Moles: Differences, Types, and Common LocationsUnderstanding Warts and Moles: Differences, Types, and Common Locations
Understanding Warts and Moles: Differences, Types, and Common Locations
 
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf
"ANATOMY AND PHYSIOLOGY OF THE SKIN".pdf
 
Basics of Giant Cell Tumor of bone (GCTB)
Basics of Giant Cell Tumor of bone (GCTB)Basics of Giant Cell Tumor of bone (GCTB)
Basics of Giant Cell Tumor of bone (GCTB)
 
Empathy Is a Stress Response - Choose Compassion instead
Empathy Is a Stress Response - Choose Compassion insteadEmpathy Is a Stress Response - Choose Compassion instead
Empathy Is a Stress Response - Choose Compassion instead
 
ARTHRITIS.pptx Prepared by monika gopal Tutor
ARTHRITIS.pptx Prepared  by monika gopal TutorARTHRITIS.pptx Prepared  by monika gopal Tutor
ARTHRITIS.pptx Prepared by monika gopal Tutor
 
Pharmacovigilance audits inspections.pptx
Pharmacovigilance audits inspections.pptxPharmacovigilance audits inspections.pptx
Pharmacovigilance audits inspections.pptx
 
The Power of Active listening - Tool in effective communication.pdf
The Power of Active listening - Tool in effective communication.pdfThe Power of Active listening - Tool in effective communication.pdf
The Power of Active listening - Tool in effective communication.pdf
 
Toothpaste for bleeding gums and sensitive teeth. Teeth whitening, Mouthwash....
Toothpaste for bleeding gums and sensitive teeth. Teeth whitening, Mouthwash....Toothpaste for bleeding gums and sensitive teeth. Teeth whitening, Mouthwash....
Toothpaste for bleeding gums and sensitive teeth. Teeth whitening, Mouthwash....
 
ACCA Version of AI & Healthcare: An Overview for the Curious
ACCA Version of AI & Healthcare: An Overview for the CuriousACCA Version of AI & Healthcare: An Overview for the Curious
ACCA Version of AI & Healthcare: An Overview for the Curious
 
LARYNGEAL CANCER.pptx Prepared by Neha Kewat
LARYNGEAL CANCER.pptx  Prepared by Neha KewatLARYNGEAL CANCER.pptx  Prepared by Neha Kewat
LARYNGEAL CANCER.pptx Prepared by Neha Kewat
 
Artificial Intelligence in Healthcare: Challenges, Risks, Benefits
Artificial Intelligence in Healthcare: Challenges, Risks, BenefitsArtificial Intelligence in Healthcare: Challenges, Risks, Benefits
Artificial Intelligence in Healthcare: Challenges, Risks, Benefits
 
Painting Rats White Angers Them to No End
Painting Rats White Angers Them to No EndPainting Rats White Angers Them to No End
Painting Rats White Angers Them to No End
 
Diseases of the Respiratory System (J00-J99),.pptx
Diseases of the Respiratory System (J00-J99),.pptxDiseases of the Respiratory System (J00-J99),.pptx
Diseases of the Respiratory System (J00-J99),.pptx
 
Eating Disorders in Athletes I Sports Psychology
Eating Disorders in Athletes I Sports PsychologyEating Disorders in Athletes I Sports Psychology
Eating Disorders in Athletes I Sports Psychology
 
SCOPE OF CRITICAL CARE ORGANIZATION
SCOPE OF CRITICAL CARE ORGANIZATIONSCOPE OF CRITICAL CARE ORGANIZATION
SCOPE OF CRITICAL CARE ORGANIZATION
 
CECT NECK NECK ANGIOGRAPHY CAROTID ANGIOGRAPHY
CECT NECK NECK ANGIOGRAPHY CAROTID ANGIOGRAPHYCECT NECK NECK ANGIOGRAPHY CAROTID ANGIOGRAPHY
CECT NECK NECK ANGIOGRAPHY CAROTID ANGIOGRAPHY
 
Living Well Every Day: Lyons Wellness Practice | Nurtures Your Complete Health
Living Well Every Day: Lyons Wellness Practice | Nurtures Your Complete HealthLiving Well Every Day: Lyons Wellness Practice | Nurtures Your Complete Health
Living Well Every Day: Lyons Wellness Practice | Nurtures Your Complete Health
 

Darren Cunningham, Inflection Bio Sciences

  • 2. 2 Overview 1 in 3 will get cancer – many will not survive *** Our mission develop groundbreaking new treatments for those suffering with cancer
  • 3. 3 Business Model DISC TARGET HITS LEAD PRE- CLIN IND PHASE 1 PHASE 2 PHASE 3 APP LAUNCH LEAD IND PACKAGE EARLY CLINICAL PRE- CLINICAL 10-15 YEAR DEVELOPMENT Value Inflection: LICENSE IN PARTNER/ EXIT/IPO 4 – 5 YEAR DEVELOPMENT
  • 4. 4 Phase I Value Creation Potential Phase I Oncology Exits $100m - >$300m
  • 5. 5 Spanish National Cancer Research Centre Collaboration with CNIO - June 2013
  • 6.  Comprising first-in-class agents protected by composition of matter patents 6 Pipeline – Targeted Therapeutics RESEARCH PRE-CLIN IND PHASE ITARGET MULTIPLE MYELOMA NSCLC IBL-202 (PIM/PI3K) IBL-300s (PIM/PI3K/mTOR) HAEM MALIGNANCIESIBL-100s (Pan-PIM) OTHER K-RAS TUMOURS B-CELL LYMPHOMAS B-CELL LYMPHOMAS Secure Partner after Phase I Secure Partner at IND
  • 7. 7 PIM Kinase a driver of resistance in AKT/PI3K 1. PIM expression dramatically elevated by PI3K/AKT pathway inhibition 2. PIM mediates feedback loop driving acquired resistance to a number of treatment modalities. Underpins rationale for co- targeting PI3K and PIM; huge clinical opportunity
  • 8. 8 IBL-300s – Targeting Molecular Subsets in NSCLC(Stage IV) EGFR TKI ResistantMutant K-RasDe novo PI3k activation Lung cancer leading cause of cancer death (1.6m ww) - NSCLC ~80% = $10bn market by 2020 Role for PI3K and PIM co-targeting in NSCLC Rationale for IBL-300s  NSCLC - K-Ras mutated in 15-30%  Downstream activation include PI3K/AKT/mTOR  PIM inhibition shuts down growth in mutant K-Ras NSCLC cell lines  NSCLC - EGFR mutations in ~10% de novo  Cancer recurs (~12mo) with ~10% due to PI3K activation  PIM elevated in EGFR TKI resistant lines  Squamous cc – PIK3CA/ PTEN mutations ~30%  PIM and PI3K inhibitors act synergistically in vitro and in vivo  PIM mediates PI3K/AKT resistance
  • 9. 9 Research Collaboration Network  Network spanning US, EU, Australia  NSCLC, pancreatic, ovarian, multiple myeloma, DLBCL, MCL, CLL, neuroblastoma, breast cancer, mechanistic
  • 10. Leadership Darren Cunningham CEO 15 year record in licensing, M&A, IP, fundraising, IR Amarin, Elan, PWC B. Comm, M. Acc, FCA Dr. Michael O’Neill Director R&D 22 year drug discovery and development  Eli Lilly, Almirall, Merck  BA Psychology, PhD MANAGEMENT ONCOLOGY ADVISORY PANEL Prof. Josep Tabernero  Director, Vall d’Hebron Institute of Oncology  Led clinical development of PI3K pathway inhibitors  ESMO Executive Board Prof. Funda Meric-Bernstam  Professor of Surgical Oncology; and  Chair Department of Investigational Cancer Therapeutics, M. D. Anderson Cancer Center Dr. Martin Page  30+ years experience in oncology R&D  Previous VP, Global Head of Oncology Res. J&J  Roles with OSI Pharma, Oxford Glycosciences, and Glaxo-Wellcome
  • 11.  Incorporated 2012  Headquartered in Dublin, with base in London  2 full time employees – Internship program, 3 in 2015 – PhD in TCD via Innovation Partnership  6 board members; panel of international scientific advisors  6 CROs (UK, France, China, India)  >10 research collaborations (US, Ireland, UK, Germany, Sweden, Australia)  ~€2.2m raised to date (EI, VC and privates) 11 Corporate profile